Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers

Krista L. Lentine, John D. Peipert, Tarek Alhamad, Yasar Caliskan, Beatrice P. Concepcion, Rachel Forbes, Mark Schnitzler, Su-Hsin Chang, Matthew Cooper, Roy D. Bloom, Roslyn B. Mannon, and David A. Axelrod

Abstract

Background Transplant practices related to use of organs from hepatitis C virus–infected donors (DHCV+) is evolving rapidly.

Methods We surveyed US kidney transplant programs by email and professional society LISTSERV postings between July 2019 and January 2020 to assess attitudes, management strategies, and barriers related to use of viremic (nucleic acid testing positive [NAT]) donor organs in recipients who are not infected with HCV.

Results Staff at 112 unique programs responded, representing 54% of US adult kidney transplant programs and 69% of adult deceased donor kidney transplant volume in 2019. Most survey respondents were transplant nephrologists (46%) or surgeons (43%). Among the responding programs, 67% currently transplant DHCV antibody+/NAT− organs under a clinical protocol or as standard of care. By comparison, only 58% offer DHCV NAT+ kidney transplantation to recipients who are HCV−, including 35% under clinical protocols, 14% as standard of care, and 9% under research protocols. After transplant of DHCV NAT+ organs to recipients who are uninfected, 53% start direct-acting antiviral agent (DAA) therapy after discharge and documented viremia. Viral monitoring protocols after DHCV NAT+ to HCV uninfected recipient kidney transplantation varied substantially. 56% of programs performing these transplants report having an institutional plan to provide DAA treatment if declined by the recipient’s insurance. Respondents felt a mean decrease in waiting time of $18 months (range, 0–60) justifies the practice. Program concerns related to use of DHCV NAT+ kidneys include insurance coverage concerns (72%), cost (60%), and perceived risk of transmitting resistant infection (44%).

Conclusions Addressing knowledge about safety and logistic/financial barriers related to use of DHCV NAT+ kidney transplantation for recipients who are not infected with HCV may help reduce discards and expand the organ supply.

Introduction

Although the kidney transplant waiting list has increased by six-fold in 20 years, deceased and living donations have not quite doubled (1). Unfortunately, kidneys from young donors with expected excellent long-term graft survival were historically discarded because of prior donor hepatitis C virus (HCV) exposure (DHCV positive antibody [Ab+]) or donor HCV viremia as detected by nucleic acid testing (DHCV NAT+). The prevalence of HCV-exposed organs, of which 25% are DHCV NAT+, has increased more than ten-fold in the last two decades as a result of opiate overdose deaths (2). Although DHCV-exposed kidney use has been increasing, thousands of kidneys have gone unused over a 10-year period (3–5).

Because DHCV Ab+/NAT− kidneys reflect prior, rather than current, infection, viral transmission to recipients is unexpected. In contrast, DHCV NAT+ kidneys result in viral transmission to the majority of recipients (6). Without effective antiviral therapy and given concerns of transmission, transplant clinicians historically confined use of DHCV NAT+ organs to recipients infected with HCV (6,7). The early introduction of direct-acting antivirals (DAAs) has...
permitted safe transplantation of DHCV NAT+ organs to patients without HCV infection (8–14). Trials from the University of Pennsylvania and Johns Hopkins demonstrated that transplantation of DHCV NAT+ kidneys into patients not infected with HCV, followed by 12 weeks of elbasvir/grazoprevir, achieved viral eradication in 100% of patients (8,9). Additional case series have followed, including groups that achieved high levels of viral clearance with shorter courses of DAA treatment, although several patients required retreatment as a result of viral resistance (12,15–18).

Despite this rapidly changing landscape, knowledge and comfort with transplantation of DHCV+ organs has not been systematically assessed. Clinical care and decision making for transplant providers is more complex for DHCV NAT+ kidneys, due to potential concerns about medical and psychosocial risks for the recipients. In addition, programs face concerns about the cost of post-treatment DAA therapy for patients, programs, and the healthcare system. The aim of this study is to examine attitudes and priorities underpinning transplant providers’ decisions about transplantation of DHCV+ viremic and nonviremic kidneys into patients without HCV infection and subsequent management.

Materials and Methods

Survey Design

The survey instrument was developed by the study investigators who developed the survey items and refined questions by direct discussion and email between them. The final survey comprised 16 questions (Supplemental Table 1). The survey queries information on participant role at the transplant program (surgeon, nephrologist, coordinator, social worker, administrator, or other) and United Network for Organ Sharing (UNOS) center identifier. Participants were asked about risk perceptions, practices, and protocols in the evaluation and management of DHCV+ transplantation for potential recipients without HCV infection. Respondents from programs that did not perform transplantation of DHCV NAT+ kidneys for patients without HCV infection were asked about perceived barriers to this practice. This study was approved to be human subjects exempt by the Saint Louis University Institutional Review Board (approval number, 30342). The clinical and research activities being reported are consistent with the principles of the Declaration of Istanbul, as outlined in the Declaration of Istanbul on Organ Trafficking and Transplantation.

Survey Administration

US kidney adult transplant programs active in 2019 (N=207), including surgeons, nephrologists, administrators, coordinators, and social workers, were surveyed. Potential participants at all US kidney transplant programs were derived from the working group’s professional connections, and the survey was emailed through the Qualtrics Survey Software. Participants from individual centers who did not wish to participate were asked to share the survey with other potential participants at their center. Surveys received from programs serving only pediatric patients were excluded from the study. Opportunity for self-elected participation through a Qualtrics link was also posted to professional society LISTSERVS, e.g., American Society of Transplantation (AST) Kidney Pancreas Community of Practice (COP) and AST Transplant Administrators and Quality Management COP, after approval by COP leadership. Links to the survey were distributed between July 15, 2019 and January 24, 2020. The first page of the survey stated the decision to proceed indicated consent to participate. Participants who completed the survey were also invited to enter a lottery for $10 coffee gift cards (20 cards were distributed). Up to three reminders were provided for nonrespondents.

Results

Survey Participants

We received 173 survey responses, of which 75 came from a program with only one survey respondent, and 98 were from programs with more than one respondent. After limiting to 115 unique program responses (Supplemental Figure 1), we removed surveys from three programs that performed only pediatric transplants, leaving 112 unique programs as the sample size for most analyses. Respondents represented 54% of US adult kidney transplant programs and 69% of adult deceased donor kidney transplant volume in 2019. Participants were most often transplant nephrologists (46%) or surgeons (43%) (Table 1). All UNOS regions were represented. The most commonly represented UNOS regions were Region 2 (14%), Region 3 (13%), and Region 11 (13%).

Transplant Program Acceptance Practices

HCV Ab+/NAT− donor organs were offered to recipients not infected with HCV by 69% of responding programs,
including 67% under a clinical protocol or as standard of care, and 2% under research protocols (Figure 1). By comparison, 58% of respondents performed DHCV NAT- kidney transplantation for recipients not infected with HCV. Transplants from DHCV NAT+ donors to recipients not infected with HCV were performed as a clinical protocol in 35% of centers, whereas 14% performed these transplants as part of standard of care and 9% under research protocols.

### Risk Perceptions
The majority of responding programs (64%) reported telling their recipients without HCV infection that there is a ≤5% risk of HCV transmission from a nonviremic donor, whereas 9% do not specifically discuss transmission risk related to these organs with patients (Table 2). Programs were then queried about patient communication regarding two specific risks after kidney transplantation from DHCV NAT+ (viremic donors) to recipients without HCV infection. First, what is the risk of chronic infection without DAA treatment? More than half of the responding programs (58%) reported a risk >50%, whereas 24% did not discuss—a counseling decision that may reflect not presenting the possibility of transplantation without DAA therapy. Second, what is the risk of chronic HCV infection with appropriate DAA therapy? Nearly all programs (95%) reported that this risk was ≤5%. Finally, on average, programs felt that a mean decrease in waiting time of ≥18 months (range, 0–60 months) justified accepting a DHCV NAT+ kidney transplantation for recipients not infected with HCV.

### Patient Eligibility and Concerns
When asked about their program’s criteria for excluding patients without HCV infection from receiving DHCV NAT+ kidney transplants, the most common responses were (allowing selection of all that apply) evidence of cirrhosis (72%), age <18 years (65%), and history of liver disease (49%). Additional, less common reasons included significant allosensitization as determined by calculated panel reactive Ab (10%), history of prior transplant (7%), and no exclusions (6%) (Figure 2).

When asked which patient concerns the participants felt were barriers to the practice of transplanting recipients

---

**Table 1. Participant characteristics**

| Characteristics                        | n (%) |
|----------------------------------------|-------|
| Role in transplant center (item denominator=112) |       |
| Transplant surgeon                     | 48 (43) |
| Transplant nephrologist                | 52 (46) |
| Administrator                          | 7 (6)  |
| Coordinator                            | 2 (2)  |
| Other                                  | 3 (3)  |
| UNOS region (item denominator=112)     |       |
| 1                                      | 9 (8)  |
| 2                                      | 16 (14) |
| 3                                      | 14 (13) |
| 4                                      | 9 (8)  |
| 5                                      | 10 (9) |
| 6                                      | 6 (5)  |
| 7                                      | 9 (8)  |
| 8                                      | 7 (6)  |
| 9                                      | 9 (8)  |
| 10                                     | 9 (8)  |
| 11                                     | 14 (13) |

UNOS, United Network for Organ Sharing.
without HCV infection with DHCV NAT+ organs, the most common responses were fear of high out-of-pocket costs for DAA medications (69%) and fear of infection (58%); less common concerns were risk of household HCV transmission (30%) and no concerns (8%) (Figure 3A). When asked which provider concerns the respondents felt were barriers to the practice of transplanting recipients without HCV infection with DHCV NAT+ kidneys, the most common responses were uncertainty about insurance coverage for DAA drugs (72%), fear of high DAA cost for the program (61%), and concern about chronic infection from viral resistance (44%). The least common responses were difficulty monitoring DAA therapy (10%) and no concern (6%) (Figure 3B).

DAA Therapy and Viral Monitoring
For programs that accept DHCV NAT+ organs for recipients without HCV infection, the majority (53%) initiated DAA therapy after discharge, after documentation of recipient viremia (Table 3). By comparison, 21% initiated therapy either at transplant or before discharge, and 14% within 4 weeks of transplant, regardless of viremia. Viral monitoring protocols after transplant from DHCV NAT+ to a recipient without HCV infection varied substantially. The most common protocol (19%) was to test for HCV RNA at transplant days 0 and 1; at DAA treatment weeks 1, 2, 3, 4, 8, and 12; and then, after DAA treatment, continue testing at weeks 2, 4, 8, and 12. Notably, 14% of respondents that reported acceptance of DHCV NAT+ organs by their center were unsure of their program’s viral monitoring protocol. Of centers providing this type of transplant, 56% had an institutional plan to provide a complete course of DAA from the transplant hospital if the recipient was declined DAA therapy by their insurance.

Discussion
This first, national survey of US transplant programs was conducted to assess utilization of kidneys from donors infected with HCV in recipients without HCV infection. With donors who are Ab+/NAT−, the risk of transmission is low and >70% of respondents reported accepting these organs for recipients without HCV infection. This was generally performed as standard of care or under clinical protocols, but seldom as part of a research study. The use of DHCV NAT+ organs is more complex because it requires the administration of DAA therapy, either at the time of transplant or once recipients become viremic. Nationally, 58% of responding programs reported accepting DHCV NAT+ organs for recipients who are uninfected. However, there is a significant diversity of approaches regarding patient education, DAA management, and viral monitoring. Programs also identified barriers to broader use of these organs, including concerns about the cost of DAA therapy to the program, insurance coverage for patients, and the risk of chronic infection due to treatment failure from resistant virus.

Although serologic testing for HCV has been widely available for more than a decade, universal NAT began

### Table 2. Risk perceptions

| Survey Question | Response, n (%)          |
|-----------------|--------------------------|
| What do you tell HCV− potential recipients about the risk of HCV transmission from nonviremic (Ab+/NAT−) donors? (item denominator=107) | |
| <5%             | 68 (64)                  |
| 5%-25%          | 16 (15)                  |
| 26%-50%         | 3 (3)                    |
| >50%            | 10 (9)                   |
| Do not discuss  | 10 (9)                   |
| What do you tell HCV− potential recipients about the risk of chronic HCV infection after KTx from donors who are HCV Ab+/NAT+ (viremic) without DAA treatment? (item denominator=107) | |
| <10%            | 14 (13)                  |
| 10%-25%         | 2 (2)                    |
| 26%-50%         | 4 (4)                    |
| 51%-75%         | 6 (6)                    |
| 76%-85%         | 2 (2)                    |
| 86%-100%        | 53 (50)                  |
| We do not discuss this possible risk | 26 (24) |
| In your view, what is the risk of chronic HCV infection due to treatment failure after KTx from donors who are HCV Ab+/NAT+ and appropriate DAA therapy? (item denominator=109) | |
| <1%             | 51 (47)                  |
| 1%-5%           | 52 (48)                  |
| 6%-10%          | 2 (2)                    |
| >10%            | 4 (4)                    |
| How much reduction in waiting time (months) do you think justifies accepting a KTx from a donor who is HCV Ab+/NAT+ (viremic) for a recipient who is HCV−, versus waiting for another deceased donor organ? Mean (range) (item denominator=108) | |

|                           | 18 (0–60)     |

HCV, hepatitis C virus; Ab, antibody; NAT, nucleic acid testing; KTx, kidney transplant; DAA, direct-acting antiviral agent.

*Indicates the item denominator, based on number of respondents, and accounting for contingent responses.
in August 2015, distinguishing viremic and nonviremic donors. A 2017 AST Consensus Conference report on use of DHCV viremic organs for transplantation opined that nonviremic organs without other risk factors are not considered to pose increased risk of HCV transmission (6,23). Studies and case reports have demonstrated that transplantation of DHCV Ab+/NAT− kidneys into recipients without HCV infection is unlikely to result in transmission (7,24). Despite these encouraging reports, our study showed that almost 30% of transplant centers do not accept DHCV Ab+/NAT− organs for recipients without HCV infection. Additionally, nearly 30% of the programs tell their potential recipients who are not infected with HCV that the risk of HCV transmission from DHCV Ab+/NAT− organs is ≥5%. Accurate information about the true risk of transmission is vital to appropriately counsel recipients, because the majority of educated patients agree to accept these organs, particularly when notified by their transplant providers that risk of HCV is minimal (7). Our survey analysis suggests there is an opportunity to improve utilization through the development of improved patient education tools that accurately report the true risk or, more accurately, the safety and benefit of transplantation with DHCV Ab+/NAT− organs for all recipients.

DAA therapy for HCV infection has revolutionized the management of HCV in the general population. The availability of pangenotypic treatments has allowed near-universal treatment success, defined as a sustained viral response at 12 weeks and no treatment-related adverse events were reported (9,25). Although these trials offered encouraging results, both studies were performed in a strict research setting, which included reliable and early availability of DAAs and close patient monitoring. Both pilot trials were industry funded with provision of DAA medications, and no third-party payers were involved. Recently, larger case series have confirmed these results (5,9,12,17,18,25–31).

Despite the published outcomes in clinical studies, the development of safe and effective strategies to use DHCV NAT− organs is challenging (10). Safe transplantation requires coordination to ensure universal post-transplant testing, access to DAAs for patients who are viremic, and appropriate monitoring to ensure compliance and viral clearance. Barriers to adoption include fear of infection, lack of insurance coverage, and concern about graft dysfunction or death after transplantation (32–35). Among the survey respondents, 42% do not accept DHCV NAT− organs for candidates who are not infected with HCV. Respondents endorsed apprehension regarding the high cost of DAAs (including out-of-pocket expenses) and uncertainty about the adequacy of patients’ post-transplant insurance coverage as barriers to use.

Among respondents, insurance coverage for DAA therapy remains a key impediment. Preemptive therapy with DAAs for patients without HCV infection who receive DHCV NAT− organs is not reimbursed by many insurance companies, requiring centers to wait to document viremia before obtaining approval or to provide medication from the center. As noted in this survey, 53% programs wait to initiate therapy after documentation of viremia, despite the early initiation practices described in early trials. Even in patients with viremia, approval is not consistent across all health insurance plans and denials occur (36–39). Recently
two single-center studies reported that the median time for DAA initiation were 76 days and 72 days after transplantation from DHCV NAT+ to recipient without HCV infection, without drug company support (15,27). Adverse outcomes have been reported in patients with delayed initiation of HCV therapy, including the development of fibrosing cholestatic hepatitis (15), that can be fatal. Finally, programs that start DAA before discharge will not receive additional reimbursement for the transplant hospitalization. This will negatively affect overall profitability of deceased kidney transplant in the current era (40). A statement by the Centers for Medicare and Medicaid Services that post-transplant HCV treatment should be covered for all beneficiaries who are Medicare eligible would reduce the risk of payment denial by Medicare intermediaries, and would likely be followed by private insurers. This should include guarantee of payment for DAAs in advance of a documented viral transmission if donor NAT testing was positive.

Despite the high cost of DAA therapy, transplantation of DHCV NAT+ kidneys to recipients not infected with HCV remains a cost saving, especially if dialysis waiting times can be significantly reduced. Two 2018 cost-effectiveness studies showed better outcomes and lower costs with DHCV-infected kidney transplantation to recipients who were uninfected compared with remaining on dialysis and waiting for a DHCV− organ, from the perspective of the healthcare system (31,41). However, payers often do not benefit from the long-term cost savings and the overall benefit of expanding the organ supply. A recent study by our group evaluated the financial breakeven point. Using current pan-genotypic regimens and estimates derived from Medicare payments, payers will reduce 3-year expenditures if waiting times are reduced by at least 11.5 months (42). In this study, respondents on average felt that 18 months reduction in waiting time justifies accepting a DHCV NAT+ for a recipient without HCV infection. Whereas prior studies have documented a reduction in waiting times for recipients, DHCV+ kidney transplants increased by 50% from 2007 to 2018. As more centers use these kidneys, the benefit of shorter waiting time will be diminished; however, this practice should remain cost effective as the cost of DAA medications and the duration of treatment decline (12).

Although DAA treatment ensured excellent allograft function and clearance of donor-derived HCV infection in pilot trials, the optimal timing of DAA therapy in HCV-uninfected kidney recipients from DHCV NAT+ is a topic of debate (9,25). No national guidelines exist regarding the timing of HCV viral screening, management, and treatment.

Figure 3. | (A) Program-reported patient concerns related to DHCV NAT+ kidney acceptance for recipients not infected with HCV. (B) Provider-reported clinical and practice concerns related to DHCV NAT+ organ acceptance for recipients without HCV infection. DAA, direct-acting antiviral agent; KTx, kidney transplant; mgmt, management.
in the acute setting after kidney transplantation from DHCV NAT+ to recipients without HCV infection. In this study, more than a third of transplant programs start DAA therapy after discharge, but only if the recipients develops HCV viremia. Respondents also did not endorse a standard approach to viremia monitoring post-transplant. Future research is needed to establish optimal clinical practices to inform national standardization of timing of viremia monitoring and DAA treatment in patients who receive DHCV NAT+ organ transplants. These guidelines may encourage further adoption of these protocols in transplant centers nationally.

There are limitations to this study. Respondents were identified by online outreach to US transplant professionals, and not all programs are represented. However, the 54% response rate is similar to or higher than many contemporary studies of transplant program practices, and the responding centers represent 69% of adult deceased-donor kidney transplant volume in the period. The findings represent practices and experiences as they are reported; we cannot verify how accurately the reports represent actual experience at the center, and we did not have access to direct data such as insurance denials for DAA therapy. Respondents may be more interested in transplantation from donors with HCV infection, which may be biased toward more favorable attitudes than at programs without participating respondents. However, a significant percentage of respondents reported their program did not transplant either DHCV Ab+/NAT+ or DHCV NAT+ kidneys. Even in cases when transplant professionals support the use of DHCV-infected organs, this may not represent the policy of their hospital leadership or local health plans.

In conclusion, this national survey of US kidney transplant programs identified diversity in attitude, monitoring, and treatment knowledge related to transplantation of DHCV NAT+ kidneys to recipients without HCV infection. Differences in transplant teams’ attitudes and care protocols may explain variability on acceptance of transplantation from DHCV NAT+ to recipients without HCV across

---

### Table 3. DAA therapy and viral monitoring

| Survey Question                                                                 | Response, n (%) |
|--------------------------------------------------------------------------------|-----------------|
| **If you accept kidneys from donors who are HCV Ab+/NAT+ for recipients who are HCV−, when do you typically start DAA therapy?** (item denominator=72) |                 |
| Before transplant (on admission or en route)                                    | 5 (7)           |
| After transplant, but before discharge                                         | 10 (14)         |
| After discharge, but within 4 wk                                               | 10 (14)         |
| After discharge, only if HCV viremic                                            | 38 (53)         |
| Other                                                                          | 9 (13)          |
| **If you accept kidneys from donors who are HCV Ab+/NAT+ for recipients who are HCV−, how long do you believe it is safe to wait to start DAA therapy?** (item denominator=68) |                 |
| At time of transplant                                                          | 6 (9)           |
| After transplant, but before discharge                                         | 8 (12)          |
| After discharge but within 2 wk, regardless of HCV viremia                     | 6 (9)           |
| After discharge but within 4 wk, regardless of HCV viremia                     | 11 (16)         |
| After discharge but only if HCV viremic                                        | 32 (47)         |
| Other                                                                          | 5 (7)           |
| **How often would you test a recipient of HCV Ab+/NAT+ donor kidney for HCV RNA after transplantation and appropriate 12 wk of DAA therapy?** (item denominator=70) |                 |
| Day 0, post-KTx day 1; DAA treatment weeks 1, 2, 3, 4, 8, and 12; after DAA treatment, continue testing at weeks 2, 4, 8, and 12 | 13 (19)         |
| Day 0, post-KTx day 1; and at DAA treatment weeks 1, 2, 3, 4, 8, and 12        | 8 (11)          |
| Post-KTx day 1, weekly during DAA treatment for 12 wk                           | 7 (10)          |
| DAA treatment weeks 4, 8, and 12                                               | 11 (16)         |
| DAA treatment weeks 4 and 12                                                    | 6 (9)           |
| Post-KTx day 1 and at the end of 12wk of DAA treatment                         | 1 (1)           |
| Other                                                                          | 14 (20)         |
| Unsure                                                                         | 10 (14)         |
| **If your program performs a transplant from a donor who is HCV Ab+/NAT+ into a recipient who is HCV− and the patient’s insurance declines DAA therapy, do you have an institutional plan to provide a complete course of medication?** (item denominator=71) |                 |
| No                                                                             | 11 (15)         |
| Yes, from the transplant hospital                                              | 40 (56)         |
| Yes, through a pharmaceutical company (e.g., grant, research)                 | 4 (6)           |
| Yes, through organ procurement organization                                     | 0 (0)           |
| Yes, through the department of surgery or department of medicine               | 2 (3)           |
| Other                                                                          | 11 (15)         |
| Unsure                                                                         | 3 (4)           |

Programs that reported not conducting transplant from donors who were HCV Ab+/NAT+ were omitted. DAA, direct-acting antiviral agent; HCV, hepatitis C virus; Ab, antibody; NAT, nucleic acid testing; KTx, kidney transplant.

*Indicates the item denominator, based on number of respondents, and accounting for contingent responses.
transplant centers. Reluctance to use DHCV NAT+ organs appears to be driven, in part, by financial and logistic concerns, which may be mitigated by revised payment mechanisms to allow immediate initiation of DAA therapy. This study highlights the need for the improvement of knowledge gaps and standardized protocols regarding the safety and efficacy to expand the organ supply through transplantation of DHCV NAT+ kidneys into patients without HCV infection in the era of DAA therapy and long waiting list times.

Disclosures
K. Lentine serves on the American Society of Nephrology (ASN) Quality Committee and reports personal consulting fees from CareDx and speaker honoraria from Sanofi, outside the submitted work. J. Peipert reports grants from Veloxis, outside the submitted work. R. Forbes reports personal fees from OrthoDiagnostics and Veloxis, outside the submitted work. Schntizer reports personal consulting fees from CareDx, outside the submitted work. R. Bloom reports reports being an advisor to Merck (2017–2018) and to Abbvie (2017–2018). R. Mannon serves on the ASN Policy Committee; reports grants from Mallinckrodt and Transplant Genomics; personal fees from Hansa, Novartis, Sanofi, and Viteaeris; and grants from Quark, outside the submitted work. D. Axelrod reports personal consulting fees from CareDx and personal advisory board fees from Veloxis and Sanofi, outside the submitted work. All remaining authors have nothing to disclose.

Funding
This work was supported by a Mid-America Transplant Clinical Innovation Award. K. Lentine is supported by the Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation and National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK120518.

Acknowledgments
The authors thank survey respondents, including members of the AST Kidney Pancreas COP and AST Transplant Administrators and Quality Management COP Listservs. An oral abstract describing portions of this work was presented at the 2020 American Transplant Congress (June 2020, virtual program).

Author Contributions
K. Lentine, T. Alhamad, M. Schntizer, and D. Axelrod conceptualized the study and were responsible for funding acquisition, project administration and resources; K. Lentine and J. Peipert were responsible for data curation, analysis, and software; T. Alhamad, Y. Caliskan, S. Chang, M. Schntizer and K. Lentine were responsible for methodology, investigation, and supervision. K. Lentine, J. Peipert, Y. Caliskan adn D. Axelrod wrote the original draft; and T. Alhamad, B. Concepcion, R. Forbes, S. Chang, M. Cooper, R. Bloom, R. Mannon, and M. Schntizer reviewed and edited the manuscript.

Supplemental Material
This article contains the following supplemental material online at http://kidney360.asnjournals.org/lookup/suppl/doi:10.34067/KID.004592021/-/DCSupplemental. Supplemental Table 1. Survey instrument.
S. Dageförde LA, Cuenca A, Kawai T, Safa K, Williams W, Gil- ligan H, Sise M, Fishman J, Kotton C, Kim A, Rogers CC, Shao S, Cote M, Irwin L, Myoung P, Chung RT: Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. *Am J Transplant* 20: 1619–1628, 2020

Molnar MZ, Nair S, Cseprekal O, Yazawa M, Talwar M, Balaraman V, Podilia PSB, Mas V, Maluf D, Helmeric RA, Campos L, Nezakatsos N, Eymard C, Horton P, Verma R, Jenkins A, Handley CR, Snyder HS, Cummings C, Agbim UA, Maliakkal B, Satapathy SK: Eason JD: Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience. *Am J Transplant* 19: 3046–3057, 2019

Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, Coppolino A, Kusztos AE, Johnson ME, Chen K, Haddad EA, Enaniks J, Harrington DP, Camp PC, Baden LR: DONATE HCV Trial Team: Heart and lung transplants from HCV-infected donors to uninfected recipients. *N Engl J Med* 380: 1606–1617, 2019

Sise ME, Strohbehn IA, Chute DF, Van Deerlin VM, Smith JR, Gentile C, Wojciechowski D, Williams WW, Elias N, Chung RT: Preemptive treatment with elbasvir and grazoprevir for hepatitis C-viremic donor to uninfected recipient kidney transplantation. *Kidney Int Rep* 5: 459–467, 2020

Pagan J, Ladino M, Roth D: Kidney transplantation from a hepatitis C-virus-infected donor into an uninfected recipient: Ready for prime time? *Kidney Int Rep* 5: 386–388, 2020

Mandelbrot DA, Pavlakis M, Danovich CM, Johnson SR, Karp SJ, Khwaja K, Hanto DW, Rodrigue JR: The medical evaluation of living kidney donors: A survey of US transplant centers. *Am J Transplant* 7: 2333–2343, 2007

Mandelbrot DA, Pavlakis M, Karp SJ, Johnson SR, Hanto DW, Rodrigue JR: Practices and barriers in long-term living kidney donor follow-up: A survey of U.S. Transplant centers. *Transplantation* 88: 855–860, 2009

Mandelbrot DA, Fleishman A, Rodrigue JR, Norman SP, Sama niego M: Practices in the evaluation of potential kidney transplant recipients who are elderly: A survey of U.S. transplant centers. *Clin Transplant* 31; 2017

Henderson ML, Clayville KA, Fisher JS, Kuntz KK, Myssel H, Purnell TS, Schaffner RL, Sherman LA, Willcock EP, Gordon EJ: Social media and organ donation: Ethically navigating the next frontier. *Am J Transplant* 17: 2803–2809, 2017

Kling CE, Perkins JD, Landis CS, Limaye AP, Sibulesky L: Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: Time for change. *Am J Transplant* 18: 2863–2868, 2017

Cruzado JM, Gil-Vernet S, Castellote J, Bestard O, Meilli E, Grinyó JM: Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient. *Am J Transplant* 13: 2773–2774, 2013

Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, Goldberg DS, Mohan S, Bloom RD, Sawinski D, Abt PL, Blumberg EA, Parikh CR, Sharpe J, Reddy KR, Molnar MZ, Sise M, Reese PP: National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. *J Am Soc Nephrol* 30: 1939–1951, 2019

Heo NY, Manannalithara A, Kim D, Udompap P, Tan JC, Kim WR: Long-term patient and graft survival of kidney transplant recipients with hepatitis C virus infection in the United States. *Transplantation* 102: 454–460, 2018

Kadatz M, Klarenbach S, Gill J, Gill JS: Cost-effectiveness of using kidneys from hepatitis C nuclear acid test-positive donors for transplantation in hepatitis C-negative recipients. *Am J Transplant* 18: 2457–2464, 2018

Sibulesky L, Javed I, Reyes JD, Limaye AP: Changing the paradigm of organ utilization from PHS increased-risk donors: An opportunity whose time has come? *Clin Transplant* 29: 724–727, 2015

Reese PP, Tehrani T, Lim MA, Asch DA, Blumberg EA, Simon MK, Bloom RD, Halpern SD: Determinants of the decision to accept a kidney from a donor at increased risk for blood-borne viral infection. *Clin J Am Soc Nephrol* 5: 917–923, 2010

Ros RL, Kucirka LM, Govindan P, Sarathy H, Montgomery RA, Segev DL: Patient attitudes toward CDC high infectious risk donor kidney transplantation: Inferences from focus groups. *Clin Transplant* 26: 247–253, 2012

Volk ML, Tocco RS, Pelletier SJ, Zikmund-Fisher BJ, Lok AS: Patient decision making about organ quality in liver transplantation. *Liver Transplant* 17: 1387–1393, 2011

Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, Sapir D, Wright J, Eggers C, Drozd K, Ciarleglio M, Deng Y, Lim JK: Drug authorization for sofosbuvir/ledipasvir (Harvoni) for chronic hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. *Am J Transplant* 9: 246–256, 2019

Kwo PY: Direct acting antiviral therapy after liver transplantation. *Curr Opin Gastroenterol* 32: 152–158, 2016

Chute DF, Chung RT, Sise ME: Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. *Kidney Int* 93: 560–567, 2018

Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X: Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. *Hepatology* 68: 1308–1317, 2018

Alhamad T, Axelrod DA, Lenti K: Chronic Kidney Disease, Dialysis, and Transplantation: A Companion to Brenner and Rector’s the Kidney, 4th Ed., edited by Himmelfarb J, Ikizler TA, Amsterdam, Elsevier, 2019

Gupta G, Zhang Y, Carroll NV, Sterling RK: Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. *Am J Transplant* 18: 2496–2505, 2018

Axelrod DA, Lenti KL, Balakrishnan D, Alhamad T, Chang S-H, Xiao H, Kasiske B, Schnitzler MA, Bloom RD: Financial analysis of donor HCV+ kidney in HCV- recipients. Presented at the 2020 American Transplant Congress, online, May 30–June 4, 2020

Received: July 29, 2020 Accepted: September 2, 2020

K.L.L. and J.D.P. contributed equally to this work.

https://www.asn-online.org/media/podcast/K360/2020_11_25_KID0004592020.mp3